

Rome, 19/01/2026

Prot. n. 27/DG

**BAMBINO GESÙ CHILDREN'S HOSPITAL
THE GENERAL DIRECTOR**

HAVING SEEN Legislative Decree no. 36 of 31 March 2023 and subsequent amendments (hereinafter the "Public Contracts Code") and subsequent amendments;

HAVING SEEN Presidential Decree No. 207 of 5 October 2010, as currently in force, which regulates the execution and implementation of the Public Contracts Code;

HAVING SEEN the contracting decision no. 155 prot. no. 519/DG of 11/13/2025, the preamble of which is hereby deemed to be fully incorporated, by which the General Director of the Bambino Gesù Children's Hospital ("OPBG") authorized the initiation of the procedure through direct award pursuant to art. 50, paragraph 1, letter b), of Legislative Decree 36/2023 for the provision of the characterization service of cell banks and viral vectors, according to standard protocols and standard reports in accordance with GMP regulations and aimed at the creation of pharmaceutical products for gene therapy to be used in Phase I/II Clinical Trials for research activities at the Tumor Gene Therapy Research Unit, belonging to the Oncohematology Research Area of the Bambino Gesù Pediatric Hospital, within the scope of the Project "Hub Life Science - Advanced Therapy (LSH-TA) PNC-E3-2022-23683269 - Funded by the Ministry of Health as part of the National Complementary Plan "Innovative Health Ecosystem" coordinated by Prof. Franco Locatelli. The above-mentioned service is provided by Solvias NL for an amount of Euro 71,705.00 (seventy-one thousand seven hundred and five/00) plus VAT, where applicable, as reported in the Contracting Decision, simultaneously appointing Dr. Monica Gunetti as The Sole Project Manager, pursuant to Article 15 of the Public Contracts Code;

HAVING SEEN the transmission on 24/11/2025 by the OPBG to the economic operator Solvias NL of the invitation letter with the related attachments, indicating

12:00 on 09/12/2025 as the deadline for participation in the tender procedure in question;

HAVING SEEN the response to the invitation letter sent by Solvias NL, acquired by the OPBG on 09/12/2025, accompanied by all required digitally signed documentation;

HAVING SEEN the evaluation document dated 09/01/2026, which examined the proposed technical offer;

HAVING SEEN the evaluation document dated 01/09/2026, with which the economic offer was assessed as appropriate for the amount of Euro 71,705.00 (seventy-one thousand seven hundred and five/00) plus VAT, where applicable, as reported in the Contract Determination;

WHEREAS the OPBG has initiated the verification of the prescribed requirements in relation to Solvias NL;

CONSIDERING that it is necessary to proceed with the awarding of the above-mentioned tender on the basis of the documents and documentation produced, necessary for the stipulation of the contract;

CONSIDERING that, as provided for by Article 17, paragraph 5 of the Public Contracts Code, the award becomes effective after positive verification of possession of the required requirements;

HAVING SEEN the CUP Code E83C22006230001 assigned by the Ministry of Health;


All of the above having been seen, considered and stated, which constitutes an integral part of this provision

ARRANGE

1. to award to the company Solvias NL based in Utrecht - The Netherlands, Yalelaan 62 3584 CM, Tax code/VAT number NL851643450B01, the procedure through direct assignment pursuant to art. 50, paragraph 1 letter. b), of Legislative Decree 36/2023 for the provision of the characterization service of cell banks and viral vectors, according to standard protocols and standard reports in accordance with GMP regulations and aimed at the creation of pharmaceutical products for

- gene therapy to be used in Phase I/II Clinical Trials for research activities at the Tumor Gene Therapy Research Unit, belonging to the Oncohematology Research Area of the Bambino Gesù Pediatric Hospital, as part of the project "Hub Life Science - Advanced Therapy (LSH-TA) PNC-E3-2022-23683269 - Funded by the Ministry of Health as part of the National Complementary Plan for the Innovative Health Ecosystem" coordinated by Prof. Franco Locatelli. The above mentioned service is provided by Solvias NL for an amount equal to Euro 71,705.00 (seventy-one thousand seven hundred and five/00) plus VAT, where applicable, as reported in the Contracting Decision;
2. that the aforementioned award becomes effective only following the positive outcome of the checks required by the legislation in force on the participation requirements;
 3. which, following the checks provided for in point 2, will be followed by the necessary formalisation of the contract;
 4. to advertise the award using the methods provided by law.

The General Director
Antonio Perno



21.1.2026